BUSINESS
Treakisym Succeeds in PIII DLBCL Study, Japan Filing Eyed in H1 2020: SymBio
Tokyo-based upstart SymBio Pharmaceuticals said on November 5 that its cancer drug Treakisym (bendamustine) met the primary endpoint in a Japan PIII study for an additional indication of diffuse large B-cell lymphoma (DLBCL). Treakisym in combination with rituximab delivered a…
To read the full story
Related Article
- Treakisym Filed for Triple Therapy in DLBCL
July 14, 2020
- SymBio Targets 11.8 Billion Yen Sales in 2022 under New 4-Year Biz Plan
February 8, 2019
BUSINESS
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





